Walker J. Wallace

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Walker J. Wallace is managing partner of O’Melveny’s Shanghai office and a leader of the firm’s China practice. He has extensive experience in international transactions and has worked with clients on a wide range of projects across Asia, from multi-nationals seeking to invest in China, to private equity funds pursuing investment strategies in Southeast Asia and elsewhere.

Walker is especially sought after for his rich experience and success in helping clients negotiate the complexities of investing and structuring business operations in China.  Over the years, this has included transactions spanning a wide range of industries, including consumer products, energy, healthcare, real estate, software, media and entertainment, retail and education.

Before moving to Shanghai in 1997, Walker practiced in New York for several years. He is currently legal advisor to The Board of Governors of The American Chamber of Commerce in Shanghai,  and previously served as Chairman of the Legal Committee.  He has written extensively on issues of Chinese law and practice, including “Onshore Financial Investing in China” and “Enforcement on Defaulted Loans and Mortgages of Real Property under Chinese Law.”

VIEW MORE

Languages

  • Mandarin Chinese

Honors & Awards

  • Recognized by IFLR1000 as a "Leading Lawyer" (2020) and "Highly Regarded" (2018-2021) in Mergers & Acquisitions and Private Equity
  • Recognized by Chambers Asia-Pacific for Corporate/M&A: China-based (International Firms) & Private Equity: Buyouts & Venture Capital Investment (International Firms) (2020 & 2021)
  • Recognized by Chambers Global 2020 & 2021 in the Corporate/M&A category for the China region
  • Asia-Pacific Legal 500 2021: Hall of Fame lawyer for the categories of M&A and Private Equity in China

Admissions

Bar Admissions

  • New York

Education

  • Columbia University, J.D., 1995: Harlan Fiske Stone Scholar
  • Williams College, B.A., 1990: cum laude
  • Numerous M&A transactions involving Chinese assets, including sale of a leading Chinese Vitamin C producer, auction of a Chinese banking subsidiary by an international conglomerate, spin-offs by multinationals of Chinese divisions and purchase of automotive financial leasing company.
  • Numerous joint ventures between US tech companies and Chinese State-owned enterprises involving satellites, networking hardware, and telephony
  • Numerous real estate transactions in China, including financings, long-term development partnerships for greenfield projects, and the acquisition and disposal of commercial and residential buildings by international financial institutions in China
  • Extensive work with private equity and venture capital funds on investments, dispositions and restructurings in China, including investment and subsequent restructuring of a leading Chinese coal bed methane company, investment in the largest out-of-home advertising company and investment in a leading Chinese company operating for-profit universities
  • Representing numerous companies to negotiate equity, mezzanine and debt financings in China
  • Structuring and negotiating RMB-denominated investment by Chinese domestic funds into offshore companies
  • Formation of small loan companies and other alternative investment structures for investing in distressed assets in China and taking collateral interests
  • Restructurings of distressed companies, including China-focused companies with failed variable interest entities
  • Negotiating the form contract used for import of all Hollywood revenue-sharing films into China
  • Market entry strategy, licensing arrangements and financings for film & television, gaming and Internet companies in China, including joint ventures for distribution, production and exhibition of film and television properties and co-production, financing and acquisition of film and television properties
  • Inversions and financings of numerous Chinese domestic companies in preparation for offshore listing
  • Market entry strategy, financings and joint ventures for new energy companies expanding to China
  • Market entry strategy and investment by life sciences funds into Chinese drug discovery and medical device opportunities, including numerous financings of drug discovery companies that have subsequently gone public
  • Purchase of non-performing loan portfolios from Chinese banks
  • Numerous transactions involving overseas investment by Chinese companies, including sale of US analog chip company to consortium of Chinese buyers and financing of Chinese iron sands project in Indonesia

Press Releases

Alerts and Publications

In the News